Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29414651 | 0.98 | TDP1 (0.48) | TDP1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL2240248 | 0.95 | TDP1 (0.50) | TDP1OPRM1OPRD1OPRK1ALDH1A1 | |
| Bromide SCHEMBL10680860 | 0.93 | TDP1 (0.48) | TDP1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL11690052 | 0.87 | MAOB (0.54) | OPRM1ALDH1A1TSHRCNR2HRH3 | |
| SCHEMBL18410710 | 0.86 | HDAC3 (0.47) | TDP1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL24097751 | 0.84 | TSHR (0.41) | TDP1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL9329761 | 0.84 | HTT (0.53) | OPRM1OPRD1OPRK1ALDH1A1TSHR | |
| SCHEMBL3256423 | 0.82 | HDAC3 (0.45) | TDP1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL4081568 | 0.81 | HTT (0.55) | OPRM1OPRD1OPRK1ALDH1A1TSHR | |
| SCHEMBL3634860 | 0.81 | HDAC3 (0.51) | TDP1OPRM1OPRD1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4439380-A | Photopolymerizable composition, especially for dental purposes | ETABLISSEMENT DENTAIRE IVOCLAR (LI) | 1984-03-27 | — | — | US | claimed |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025245178-A1 | PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | INNOVO THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120157686-A | Compound with AKT kinase degradation activity, preparation method and pharmaceutical application thereof | 南京正大天晴制药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4565323-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | Rappta Therapeutics Oy (FI) | 2025-06-11 | — | — | EP | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2017144900-A1 | MASS SPECTROMETRY KIT | THE BINDING SITE GROUP LIMITED (GB) | 2017-08-31 | — | — | WO | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| EP-2414366-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2010112520-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2010-10-07 | — | — | WO | disclosed |
| EP-0562624-A2 | Stabilization of functional proteins | Modrovich, Ivan E. (US) | 1993-09-29 | — | — | EP | disclosed |
| US-4489710-A | Composition and method for transplantation therapy | XOMA CORPORATION (US) | 1984-12-25 | — | — | US | disclosed |
| US-4439380-A | Photopolymerizable composition, especially for dental purposes | ETABLISSEMENT DENTAIRE IVOCLAR (LI) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TDP1 4607/4885OPRM1 3204/4885OPRD1 1176/4885 |
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC2R, MC1R, MC3R | TDP1 4859/4885OPRM1 87/4885OPRD1 65/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | TDP1 3036/4885OPRM1 1303/4885OPRD1 406/4885 |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | TDP1 2453/4885OPRM1 4682/4885OPRD1 4274/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | TDP1 652/4885OPRM1 4825/4885OPRD1 4776/4885 |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | TDP1 3253/4885OPRM1 495/4885OPRD1 778/4885 |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC1R, MC3R, MC2R | TDP1 4822/4885OPRM1 137/4885OPRD1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.